Release Date: January 2016Company Wide License (Global Site): USD 6,500
Number of Pages: 187
Number of Tables and Figures: 46
Synopsis: With an aging world population and rising expectations about skin, hair, and nail appearance, the prevalence of some of the most common skin disorders continues to rise. With the exception of Melanoma, most skin disorders are not life threatening. However, they can have serious effects on daily life by causing visible physical damage, embarrassment, and social and occupational restrictions.
Although surgery and other therapies are widely used for the treatment of certain skin conditions, dermatological drugs continue to account for the highest percentage of spending within the wider market for dermatological products. Expected to reach nearly $23 Billion in global spending by the end of 2016, dermatological drugs remain the preferred approach to treat common skin disorders, ranging from Acne to more complicated conditions such as Psoriasis. Despite the loss of patent protection for several blockbuster drugs which has attracted generic competition, the market is ripe for future growth with a number of novel drugs in late-stage development.
The “Dermatological Drugs Market: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for dermatological drugs from 2016 through to 2030. The forecasts are segmented for over 7 therapeutic categories, 5 regions and 25 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a sample of the report or any further inquiries please contact email@example.com
Pricing: The report is available for the following price:
Single User License: USD 2,500
Company Wide License (Single Site): USD 3,500
The report has the following key findings:
The report covers the following topics:
Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
Key Questions Answered:
The report provides answers to the following key questions:
List of Companies Mentioned:The following companies and organizations have been reviewed, discussed or mentioned in the report:
BMS (Bristol-Myers Squibb)
Dr. Reddy's Laboratories
Eli Lilly and Company
FDA (Food and Drug Administration)
G&E Corporation (G&E Herbal Biotechnology)
Johnson & Johnson
JT (Japan Tobacco)
Mayne Pharma Group
Merck & Co.
Nestle Skin Health
Pierre Fabre (Laboratoires Pierre Fabre)
Roche Holding (F. Hoffmann-La Roche)
Sun Pharma (Sun Pharmaceutical Industries)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
The Medicines Company
Torii Pharmaceutical Company
University of Pennsylvania